These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 19594354

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA.
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
    [Abstract] [Full Text] [Related]

  • 3. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
    Dolezal J, Vizda J, Odrazka K.
    Urol Int; 2007 Apr; 78(1):50-7. PubMed ID: 17192733
    [Abstract] [Full Text] [Related]

  • 4. Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?
    Waldert M, Klatte T, Remzi M, Sinzinger H, Kratzik C.
    World J Urol; 2012 Apr; 30(2):233-7. PubMed ID: 21559805
    [Abstract] [Full Text] [Related]

  • 5. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
    Macedo A, Araújo A, Melo FC, Nunes G, Cantinho G, Amorin I.
    Acta Med Port; 2006 Apr; 19(5):421-6. PubMed ID: 17376329
    [Abstract] [Full Text] [Related]

  • 6. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
    Skalli S, Desruet MD, Bourre JC, Caravel JP, Vuillez JP.
    Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
    [Abstract] [Full Text] [Related]

  • 7. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Liepe K, Kotzerke J.
    Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
    [Abstract] [Full Text] [Related]

  • 8. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Liepe K, Runge R, Kotzerke J.
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
    [Abstract] [Full Text] [Related]

  • 9. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A.
    J Clin Oncol; 2009 May 20; 27(15):2429-35. PubMed ID: 19364971
    [Abstract] [Full Text] [Related]

  • 10. [Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].
    Feng JY, Wu CQ, Zhang P, Wang SJ, Zheng XH.
    Zhonghua Nan Ke Xue; 2012 Nov 20; 18(11):982-5. PubMed ID: 23214246
    [Abstract] [Full Text] [Related]

  • 11. Samarium-153-lexidronam therapy for metastatic bone pain.
    Ribera H.
    J Pain Palliat Care Pharmacother; 2013 Mar 20; 27(1):80-1; discussion 81-2. PubMed ID: 23527672
    [Abstract] [Full Text] [Related]

  • 12. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.
    Wang RF, Zhang CL, Zhu SL, Zhu M.
    Med Princ Pract; 2003 Mar 20; 12(2):97-101. PubMed ID: 12634464
    [Abstract] [Full Text] [Related]

  • 13. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S, Finkelberg E, Varisco D, Tondelli E, Rocco F.
    Urologia; 2011 Mar 20; 78(4):300-4. PubMed ID: 22139807
    [Abstract] [Full Text] [Related]

  • 14. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A, Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M, Ronga G.
    Clin Ter; 2009 Mar 20; 160(3):193-9. PubMed ID: 19756320
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.
    Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G.
    Eur J Nucl Med Mol Imaging; 2007 Jul 20; 34(7):1023-30. PubMed ID: 17242920
    [Abstract] [Full Text] [Related]

  • 16. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T.
    Int J Urol; 2012 Feb 20; 19(2):169-73. PubMed ID: 22126137
    [Abstract] [Full Text] [Related]

  • 17. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T, Kawashima H, Kuratsukuri K, Sugimura K, Nakatani T.
    Hinyokika Kiyo; 2006 Jun 20; 52(6):491-4. PubMed ID: 16848364
    [Abstract] [Full Text] [Related]

  • 18. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
    Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E.
    Support Care Cancer; 2007 Mar 20; 15(3):339-42. PubMed ID: 16967302
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
    Dolezal J.
    Onkologie; 2009 Feb 20; 32(1-2):35-9. PubMed ID: 19209017
    [Abstract] [Full Text] [Related]

  • 20. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
    Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C, Correa-Hernández L.
    Arch Med Res; 2014 May 20; 45(4):301-8. PubMed ID: 24681187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.